{
  "docId": "019de075-b7fd-707e-9848-cbfca2408f7c",
  "docSlug": "18b92232553b1610a38c1cd353f6efa7",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 28 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 2,
  "pageCount": 28,
  "prevPage": 1,
  "nextPage": 3,
  "slideType": "thesis_headline",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide uses a three-column layout to contrast the lead asset with the two core technology platforms.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-b7fd-707e-9848-cbfca2408f7c/2",
  "deckHref": "/decks/019de075-b7fd-707e-9848-cbfca2408f7c",
  "deckJsonHref": "/decks/019de075-b7fd-707e-9848-cbfca2408f7c.json",
  "deckAnchorHref": "/decks/019de075-b7fd-707e-9848-cbfca2408f7c#slide-2",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.75,
        "x": 0.19,
        "y": 0.15
      },
      "kind": "callout",
      "text": "Clinically validated, Phase 3-ready asset, 12 years of Exclusivity, $750mm – $1B billion Annual Global Annual Sales Potential",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "744fa8fd-391b-4164-b012-d153e082e2c5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.26,
        "x": 0.4,
        "y": 0.525
      },
      "kind": "list",
      "text": "PS-NP Platform: Phosphatidylserine Nanoparticles, Delivery of larger oligos, Successful delivery mRNA in vivo",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "29da6784-cb17-46ef-9843-45f98fc78a39",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.26,
        "x": 0.09,
        "y": 0.525
      },
      "kind": "list",
      "text": "LNC Platform: Lipid Nanocrystals, Stable, Improved Safety, Targets Cells, Oral delivery",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4837b3f2-21b3-44c7-b074-3334313e1004",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.26,
        "x": 0.72,
        "y": 0.525
      },
      "kind": "list",
      "text": "Internal and External Pipelines: Internal focus on infectious disease, inflammation, cancer; External collaborations with National Resilience and Genentech",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d515b8bb-9465-49dc-8390-253f4ed6b0b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "Matinas Investment Thesis: Intracellular Delivery Unlocks Therapeutic Value",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9af19a7b-58f4-48ed-9b72-4507a34faf2f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}